Table 4.
Co-payment for suboptimal treatments. The implications of 4 different policies on provision of hypothetical drugs
| Axemab | Boxemab | Cliximab | Daxamab | |
|---|---|---|---|---|
| Cost (pounds) | 10,000 | 10,000 | 20,000 | 10,000 |
| Effect | 1 | 0.5 | 1.5 | 0.02 |
| Cost/QALY (pounds)* | 10,000 | 20,000 | 13,333 | 500,000 |
| Optimal treatment | ✓ | |||
| CE | ✓ | ✓ | ✓ | ✓ |
| CEE | ✓ | **£3333 | ✓ | **£9733 |
| CETE | ✓ | ✓ | ✓ | **£9400 |
Optimal treatment is highlighted in bold
* Incremental cost-effectiveness—compared with standard treatment
✓ Indicates that the drug would be provided without co-payment
** Numerical values indicate the patient co-payment (or price reduction) required to render the suboptimal treatment cost-equivalent